Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-03-15
2001-10-09
Reamer, James H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06300336
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to the use of 4-chloro-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-methoxy-2-methylpyrimidine (=moxonidine) and the physiologically compatible acid addition salts thereof for the treatment and/or prophylaxis of functional gastrointestinal disturbances and illnesses in the region of the lower intestinal tracts, in particular for the treatment and/or prophylaxis of abdominal visceral pain which accompanies them, and to the preparation of medicaments suitable for this treatment and/or prophylaxis.
SUMMARY OF THE INVENTION
It is an object of the invention to provide a new method for the treatment of functional and/or illness-related symptoms in the region of the lower intestinal tracts, and in particular, for example, for the treatment and/or inhibition of abdominal visceral pain which accompanies them.
According to the invention, 4-chloro-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-methoxy-2-methylpyrimidine of the general Formula I
or a physiologically compatible acid addition salt thereof is used for the preparation of pharmaceutical preparations for the treatment and/or inhibition of functional disturbances and illnesses of the lower intestinal tracts which involve increased sensitivity to pain in the colon region, preferably for the treatment and/or prophylaxis of abdominal visceral pain which accompanies them, in larger mammals and humans.
Suitable physiologically compatible acid addition salts of moxonidine include salts with inorganic acids, for example hydrohalic acids, or with organic acids, for example lower aliphatic monocarboxylic or dicarboxylic acids, such as acetic acid, fumaric acid or tartaric acid, or aromatic carboxylic acids such as salicylic acid.
The compounds used according to the invention fall within the scope of 5-[(2-imidazolin-2-yl)-amino]-pyrimidine derivatives having hypotensive properties as described in German Patent Application No. DE 28 49 537, and are known from this patent application. Pharmaceutical preparations which contain moxonidine are commercially available as antihypertensive agents under the trade name Physiotens™, and are medicinally used as antihypertensive agents. The compounds may be prepared in known manner according to the methods described in the above patent application, or analogously to these methods. Moxonidine and its physiologically acceptable salts have also been found to have hyperglycemia inhibiting activity (See U.S. Pat. Nos. 5,972,948 and 5,712,283) and to exert a nephroprotective function (See U.S. Pat. No. 5,914,330).
It has now surprisingly been found that moxonidine and its physiologically compatible acid addition salts not only are suitable for the treatment of illnesses of the cardiovascular system, such as in particular for the treatment of hypertension, as stated in the German patent application cited above, but also can be used for the treatment and/or prophylaxis of functional disturbances and illnesses of the lower intestinal tracts. Moxonidine and the physiologically compatible acid addition salts thereof are suitable in particular for the treatment and/or prophylaxis of abdominal visceral pain which accompanies these functional disturbances and illnesses.
The functional disturbances which can be treated by the compounds used according to the invention therefore include in particular the disturbances of the lower intestinal tracts which are called “irritable bowel syndrome” (=IBS). The essential symptoms of IBS are pain in the lower abdomen, which is considerably jointly caused by hypersensitivity of the visceral afferent nervous system. The increased visceral sensitivity to pain with respect to mechanical or chemical stimuli in the intestinal tract results in IBS patients suffering severe visceral pain even with only physiological slight distension of the colon owing to digestion, e.g. even with only slight gas formation and slight flatulence, which are scarcely noticed by healthy individuals. The symptoms observed what is called “irritable bowel syndrome” (=IBS) include, in addition to motility disturbances in the lower intestinal region and disturbances of stool passage, such as in particular abnormally accelerated passage of the stool in the colon, and therefore to a particular extent also visceral pain. The compounds used according to the invention in this case have a beneficial action with marked action components with respect to visceral pain in the colon.
Disturbances in the gastrointestinal tract may also be caused by inflammatory diseases, such as diseases like those grouped under the term “inflammatory bowel disease” (IBD), which may likewise involve increased visceral sensitivity to pain.
It has now been discovered that moxonidine and its pharmacologically acceptable acid addition salts reduce visceral sensitivity to pain. Owing to their beneficial action on abdominal visceral sensitivity to pain, moxonidine and its pharmacologically acceptable acid addition salts are therefore suitable in particular for the treatment and/or prophylaxis of abdominal visceral pain, such as may occur in particular in conjunction with IBS or IBD.
Moxonidine and its physiologically compatible acid addition salts may be administered in conventional pharmaceutical preparations, orally, intravenously or alternatively transdermally for the treatment according to the invention of illnesses and functional disturbances and illnesses of the lower intestinal tracts, in particular for example for the treatment and/or prophylaxis of visceral pain which accompanies them.
Thus moxonidine and its physiologically compatible acid addition salts may be contained, together with conventional pharmaceutical auxiliaries and/or carriers, in solid or liquid pharmaceutical preparations, in a quantity effective for the treatment of functional disturbances and illnesses of the lower intestinal tracts, in particular, for example, in a quantity effective for the treatment and/or inhibition of visceral pain which accompanies them. Examples of solid preparations which may be formulated for the direct or delayed release of active substance include preparations which can be administered orally, such as tablets, coated tablets, capsules, powders or granules, or alternatively suppositories and plasters (transdermal therapeutic systems). These solid preparations may contain conventional pharmaceutical inorganic and/or organic carriers, such as lactose, talcum or starch, in addition to conventional pharmaceutical auxiliaries, for example lubricants or tablet disintegrating agents. In the case of plasters, the active substance is kept in an active-substance reservoir, in particular, for example, an active-substance matrix (e.g. a polymer matrix). Liquid preparations such as solutions, suspensions or emulsions of the active substances may contain the usual diluents such as water, oils and/or suspension agents such as polyethylene glycols and the like. Other auxiliaries may additionally be added, such as preservatives, taste correctives and the like.
The active substances may be mixed and formulated with the pharmaceutical auxiliaries and/or carriers in known manner. For the production of solid medicament forms, the active substances may for example be mixed with the auxiliaries and/or carriers in conventional manner and may be granulated in the wet or dry state. The granules or powder may be poured directly into capsules or be pressed into tablet cores in conventional manner. These may be coated in known manner if desired. Plasters or transdermal therapeutic systems may be constructed in the conventional manner e.g. from a covering film, active-substance reservoir (self-adhesive or with additional adhesive layer) and tear-off film and as matrix-controlled or membrane-controlled systems (i.e. equipped with an additional control membrane).
The pharmacological activity of moxonidine and its pharmacologically acceptable acid addition salts in the region of the lower intestinal tracts can be demonstrated in standard pharmacological tests on animals.
Eeckhout Christian
Sann Holger
Crowell & Moring LLP
Reamer James H.
Solvay Pharmaceuticals GmbH
LandOfFree
Method of treating or inhibiting functional disturbances or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating or inhibiting functional disturbances or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating or inhibiting functional disturbances or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2576090